Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a cornerstone of adult heart failure (HF) therapy and are increasingly prescribed off-label to children, yet pediatric outcomes have never been pooled. We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science to 14 August 2026 for studies of any SGLT2 inhibitor in children or adolescents with HF and performed a single-arm meta-analysis of all exposed patients and a pairwise meta-analysis of the comparative studies with random-effects models. Nine studies contributed 599 exposed patients and 97 controls. Pooled rates were 3.8% (95% confidence interval [CI] 1.6-8.4) for mortality, 8.5% (6.2-11.5) for transplantation, 11.2% (8.2-15.1) for worsening HF, 0.2% (0.03-1.6) for ketoacidosis, 4.5% (1.2-14.9) for acute kidney injury, 3.7% (1.1-11.7) for urinary tract infection, and 4.1% (1.4-11.2) for discontinuation because of an adverse event. After initiation, left ventricular ejection fraction rose by 7.7 percentage points (3.6-11.8) and natriuretic peptide fell by 0.42 standard deviations (0.34-0.49). In the comparative synthesis (63 exposed, 97 unexposed), risk ratios were 0.80 (0.11-6.07) for mortality and 0.21 (0.03-1.68) for worsening HF; ejection fraction improved 3.34 percentage points more with SGLT2 inhibitors (0.22-6.46) whereas natriuretic peptide did not differ (standardized mean difference -0.09, -0.50 to 0.33).
SGLT2 inhibitorsheart failurepediatric heart failurechildren and adolescents
BACKGROUND: Direct-Acting Antivirals (DAAs) are effective in 95% of patients, but concerns about potential cardiotoxicity and decreased Warfarin Sensitivity (WS) need further investigation. The study aimed to evaluate the safety and effectiveness of sofosbuvir-based therapy in patients with significant heart diseases, considering potential drug interactions and their impact on cardiac function. METHODS: The study involved 100 patients with HCV genotype 4, including 40 with ischemic heart disease, 20 with prosthetic valve replacement, 20 with NYHA class I‒II heart failure, and 20 with systemic hypertension. All received sofosbuvir-based antiviral therapy and underwent routine laboratory tests, N-Terminal B-type Natriuretic Peptide (NT-Pro BNP), abdominal ultrasound, and echocardiography at baseline and three months post-treatment. RESULTS: Ninety-six patients achieved SVR, resulting in improved cardiac ejection fraction (EF) from 53.2 ± 8.8% to 56.2 ± 6.9% (p = 0.000) and reduced left atrial volume (LAV) from 43.2 ± 4.2 to 41.7 ± 3.9 mm (p = 0.008). Liver stiffness also improved (p = 0.013), and no disabling symptoms were reported. MAPSE increased from 8.4 ± 2.4 mm to 9.5 ± 2.5 mm, and interventricular septum thickness (IVT) decreased from 12.5 ± 1.8 mm to 10.9 ± 1.3 mm (p = 0.001 and P = 0.000, respectively). The warfarin dose needed to be increased to optimize INR after SVR, but this adjustment did not affect WS (p = 0.16). CONCLUSION: Sofosbuvir-based antiviral therapy was well tolerated and demonstrated a reassuring cardiac safety profile in HCV patients with pre-existing heart disease, with no major arrhythmias or adverse cardiac events observed during or after therapy.
Abstract Purpose Angiotensin receptor-neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety when initiated in acute decompensation (ADHF) remain less well characterized. This meta-analysis evaluates the efficacy and safety of ARNI compared to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for ADHF. Methods A meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, Scopus, WOS, Embase, and CENTRAL till November 2024. Risk ratios (RR) were applied for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes, both with 95% confidence intervals (CI). Results Three RCTs with 1,741 patients were included. Use of ARNI after stabilization of ADHF resulted in a significant reduction of HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57 to 0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57 to 0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64 to 1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: -0.24; 95% CI: -0.34 to -0.14; p < 0.0001) or 8 weeks (SMD: -0.21; 95% CI: -0.31 to -0.10; p = 0.0001). However, ARNI was associated with a higher risk of symptomatic hypotension (RR: 1.33; 95% CI: 1.04 to 1.71; p = 0.024). Conclusion Pooled data demonstrate that the initiation of ARNI post-ADHF can be effective compared with ACEIs/ARBs for both cardiovascular and renal benefits at the expense of increased risk for symptomatic hypotension.
Background Angiotensin receptor – neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety after stabilization of acute decompensation (ADHF) remain unclear. This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF.Methods Meta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, WOS, Embase, and CENTRAL up to November 2024. Risk ratios (RR) and standardized mean differences (SMD) with 95% confidence intervals (CI) were used.Results Three RCTs (1,741 patients) were included. ARNI use after ADHF stabilization significantly reduced HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57–0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57–0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64–1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: −0.24; 95% CI: −0.34 to −0.14; p < 0.0001) and 8 weeks (SMD: −0.21; 95% CI: −0.31 to −0.10; p = 0.0001). However, ARNI increased symptomatic hypotension risk (RR: 1.33; 95% CI: 1.04–1.71; p = 0.024).Conclusion initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.Protocol registration PROSPERO: CRD42024618027.
Abstract Background Coronary artery bypass surgery is recommended for patients with extensive coronary artery disease and severely impaired left ventricular ejection fraction (LVEF). Short term clinical outcomes improved due to advanced surgical techniques and perioperative management. Objective To study the impact of pre-operative left ventricular ejection fraction (LV EF) on clinical outcomes during postoperative hospitalization and for 5 years follow up. Methods The study was a retrospective analysis of patients underwent CABG at our tertiary care hospital between January 2016 and August 2020.The primary outcome was mortality and the secondary outcomes included acute cerebrovascular stroke, length of hospitalization, subsequent revascularization, and heart failure. Results The study included 410 patients with a median age of 60 (55–68) years, a hospital mortality of 2.7%, postoperative stroke of 7.6%, acute kidney injury (AKI) of 25.6% and new need dialysis of 5.9%. The patients were divided into 4 groups: 75 (18.3%) patients had LV EF less than 35%, 88 (21.5%) had LV EF 35–45%, 106 (25.9%) had LV EF 45–55% and 141 (34.4%) had LV EF more than 55% with significant differences in frequencies of chronic kidney disease (29.3% vs. 40.9% vs. 23.6% vs. 24.1%, p=0.026), prior cerebral stroke (9.3% vs. 11.4% vs. 8.5% vs. 1.4%, p=0.015), Peripheral vascular disease (8% vs. 18.2% vs. 4.7% vs. 12.1%, p=0.019) respectively. The hospital mortality occurred in (6.7% vs. 0% vs. 0.9% vs. 3.5%, p=0.03), acute cerebrovascular stroke occurred in (14.7% vs. 6.8% vs. 3.8% vs. 7.1%, p=0.031), AKI occurred in (36% vs. 43.2% vs. 17.9% vs. 14.9%, p<0.001), new dialysis was used in (12% vs. 5.7% vs. 1.9% vs. 5.7%, p=0.04), ICU stay was [5 (3–7) vs. 4 (3–11) vs. 4 (3–5) vs. 3 (2–5), p<0.001], post ICU stay was [6 (3–10) vs. 5 (4–8) vs. 4 (3–6) vs. 4 (3–6), p=0.009] in patients with LV EF <35%, LV EF 35–45%, LV EF 45–55% and LV EF >55% respectively. Mortality during follow up occurred in (20% vs. 4.5% vs. 2.8% vs.4.3%, p<0.001), stroke occurred in (8% vs. 4.5% vs.0.9 5% vs. 2.8%, p=0.031), revascularization was done in (2.7% vs. 23.9% vs. 18.9% vs. 12.8%, p=0.009) and readmission with heart failure occurred in (52% vs. 34.1% vs. 10.4% vs. 4.3%, p<0.001) in patients with LV EF <35%, LV EF 35–45%, LV EF 45–55% and LV EF >55% respectively. Conclusion Reduced LV EF was associated with increased hospital mortality, frequent morbidities, and prolonged hospitalization after CABG with higher composite rate of death, stroke, heart failure at 5 years compared with normal or mildly reduced LV EF. Funding Acknowledgement Type of funding sources: None.
left ventricular ejection fractioncoronary artery bypass graftingpreoperative cardiac functionpostoperative mortality